Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2008

View Archived Issues

Paclitaxel plus bevacizumab combination active in metastatic breast cancer

Pfizer's pan-ERBB inhibitor shows preclinical efficacy in gefitinib-resistant lung cancer

Somaxon completes 26-week transgenic mouse carcinogenicity study of Silenor

Lung and renal improvement with sirolimus in tuberous sclerosis complex and LAM / News in Context

Arcion raises funds in Series A financing to help develop ARC-4558 for pain

Anthera obtains rights from Amgen for AMG-623 for systemic lupus erythematosus

Celltrion and CSL sign agreement for CSL-360 for acute myeloid leukemia

Arena's APD-791 for arterial thrombosis well tolerated in phase Ia clinical trial

Update on Cipher's appeals of approvable letters for CIP-isotretinoin and CIP-tramadol

Novacea scales back clinical development of anticancer prodrug banoxantrone

Amarin to initiate phase IIa trial of AMR-101 for age-associated memory impairment

FDA grants expanded indication for general hemostasis in surgery for Omrix's Evicel

FDA accepts for filing BioDelivery Sciences' NDA for BEMA Fentanyl for cancer pain

New compounds for hypertension and other cardiovascular disorders described

Recent patents describe novel agents for neurological disorders

Celtic Pharma and Inspiration sign agreement for development of Factor IX for hemophilia B

Hammersmith Imanet patents novel diagnostic agents

Positive preclinical results with Abbott's new DGAT-1 inhibitor reported

Transgene reports positive preliminary data from phase IIb of TG-4010 for advanced NSCLC

FDA and Ardana reach agreement on clinical development of teverelix LA for endometriosis

FDA Anti-infective Drug Advisory Committee grants review for Basilea's ceftobiprole

FDA grants orphan drug designation to Curacyte's hemoximer for cardiogenic shock

ImmuPharma gains rights to nucleolin antagonist IPP-204106 for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.